Cellerix, SL: Series C $37.7M

Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Crohn's, X - GI, X - Stem Cell

Cellerix (Spain) a clinical-stage biopharma company focused on adult stem cell therapies for Crohn’s and other GI diseases, closed a $37.7M Series C financing. Participants include Ysios Capital Partners, Ventech, Roche Venture Fund and Novartis Venture Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Alvine Pharmaceuticals, Inc.: Series A $21.5M

Posted in I - Series A, Q - 3Q09, R - WEST, X - Autoimmune, X - Celiac, X - GI, XX - CA

Alvine Pharmaceuticals (San Carlos, CA) a clinical-stage biopharmaceutical company focused on autoimmune related GI disease such as Celiac disease, closed a $21.5M financing bringing the total round to $47.5M. Participants include Panorama Capital, InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures.

Hyperion Therapeutics, Inc.: Series C $60M

Posted in I - Series C, Q - 2Q09, R - WEST, X - GI, X - Hepatology, XX - CA

Hyperion Therapeutics (San Francisco, CA) a clinical-stage specialty pharmaceutical company focused on gastroenterology and hepatology, closed a $60M Series C financing. Participants include Bay City Capital, Panorama Capital, Highland Capital Partners, New Enterprise Associates, Sofinnova Ventures, and WRF Capital.

ActoGeniX, NV: Series B $17.1M

Posted in I - Series B, Q - 1Q09, R - INTERNATIONAL, X - GI, X - Metabolism

ActoGeniX (Belgium) a clinical-stage biopharmaceutical company focused on the development
of protein therapeutics for the treatment of gastrointestinal and metabolic diseases, closed a $17.1M Series B financing. Participants include Biovest, Gimv, Biotech Fund Flanders, Baekeland Fund, VIB, LSP, Aescap Venture and Ventech.

Baronova, Inc.: Series B $7.5M

Posted in I - Series B, Q - 4Q08, R - WEST, X - Device (Obesity), X - GI

Baronova (Goleta, CA) developer of medical devices for the treatment of obesity, closed a $7.5M Series B financing. Participants include Allergan, Arboretum Ventures, Highland Capital Partners and Onset Ventures.

ACT Biotech, Inc.: Series A $12M

Posted in I - Series A, Q - 2Q08, R - WEST, X - GI, X - Oncology

ACT Biotech (San Francisco, CA) focused on developing and commercializing targeted oral and GI cancer drugs, closed a $12M Series A financing. Participants include NGN Capital.

Albireo Pharma, AB: Series A $40M

Posted in I - Series A, Q - 2Q08, R - INTERNATIONAL, X - GI

Albireo Pharma (Sweden) focused on developing therapies in the GI and chronic constipation, closed a $40M Series financing. Participants include Nomura Phase4 Ventures, TVM Capital Scottish Widows Investment Partnership and TPG Growth.

Ocera Therapeutics, Inc. Series C $35.5M

Posted in I - Series C, Q - 1Q08, R - WEST, X - GI

Ocera Therapeutics (San Diego, CA) a clinical stage company focused on gastrointestinal and liver diseases closed a $35.5M Series C financing. Participants include Montagu Newhall Associates, InterWest Partners, AgeChem Venture Fund, Cross Creek Capital, FinTech, CDIB BioScience, Domain Associates, Sofinnova Ventures and Thomas, McNerney & Partners.

Gelesis, Inc.: Series A $16.0M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - GI, X - Obesity

Gelsis (Boston, MA) is developing a breakthrough treatment for obesity and other gastrointestinal disorders has closed a $16M Series A. Participants include OrbiMed, Queensland BioCapital Funds, PureTech Ventures, Lansing Brown Investments and the Cape Family Fund.

Microbia, Inc.: Series F $50M

Posted in I - Series F, R - NORTH EAST, X - Cardiology, X - GI

Microbia (Cambridge, MA) rational drug designer focused on GI and cardiovascular therapeutics raised a $50M series F round. The financing was led by Ridgeback Capital and joined by Morgan Stanley Investment Management.

to top of page...